Sex matters in CSU: Women face greater burden and poorer urticaria control, especially in midlife—CURE insights
1
Issued Date
2025-01-01
Resource Type
ISSN
09269959
eISSN
14683083
Scopus ID
2-s2.0-105016485298
Journal Title
Journal of the European Academy of Dermatology and Venereology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the European Academy of Dermatology and Venereology (2025)
Suggested Citation
Kocatürk E., Salameh P., Asero R., Bizjak M., Gimenez-Arnau A., Grattan C., Pesqué D., Planella-Fontanillas N., Herzog L.S., Buttgereit T., Bonnekoh H., Fomina D., Kovalkova E., Lebedkina M., Kasperska-Zajac A., Zając M., Zamłyńsk M., Kulthanan K., Tuchinda P., Khoshkhui M., Hassanpour Z., Peter J., Du-Thanh A., Meshkova R., Abuzakouk M., Makris M., Bouillet L., Bocquet A., Gregoriou S., Thomsen S.F., Dissemond J., Staubach P., Bauer A., Danilycheva I., van Doorn M., Parisi C., Metz M., Fluhr J.W., Zuberbier T., Weller K., Kolkhir P. Sex matters in CSU: Women face greater burden and poorer urticaria control, especially in midlife—CURE insights. Journal of the European Academy of Dermatology and Venereology (2025). doi:10.1111/jdv.70027 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112285
Title
Sex matters in CSU: Women face greater burden and poorer urticaria control, especially in midlife—CURE insights
Author(s)
Kocatürk E.
Salameh P.
Asero R.
Bizjak M.
Gimenez-Arnau A.
Grattan C.
Pesqué D.
Planella-Fontanillas N.
Herzog L.S.
Buttgereit T.
Bonnekoh H.
Fomina D.
Kovalkova E.
Lebedkina M.
Kasperska-Zajac A.
Zając M.
Zamłyńsk M.
Kulthanan K.
Tuchinda P.
Khoshkhui M.
Hassanpour Z.
Peter J.
Du-Thanh A.
Meshkova R.
Abuzakouk M.
Makris M.
Bouillet L.
Bocquet A.
Gregoriou S.
Thomsen S.F.
Dissemond J.
Staubach P.
Bauer A.
Danilycheva I.
van Doorn M.
Parisi C.
Metz M.
Fluhr J.W.
Zuberbier T.
Weller K.
Kolkhir P.
Salameh P.
Asero R.
Bizjak M.
Gimenez-Arnau A.
Grattan C.
Pesqué D.
Planella-Fontanillas N.
Herzog L.S.
Buttgereit T.
Bonnekoh H.
Fomina D.
Kovalkova E.
Lebedkina M.
Kasperska-Zajac A.
Zając M.
Zamłyńsk M.
Kulthanan K.
Tuchinda P.
Khoshkhui M.
Hassanpour Z.
Peter J.
Du-Thanh A.
Meshkova R.
Abuzakouk M.
Makris M.
Bouillet L.
Bocquet A.
Gregoriou S.
Thomsen S.F.
Dissemond J.
Staubach P.
Bauer A.
Danilycheva I.
van Doorn M.
Parisi C.
Metz M.
Fluhr J.W.
Zuberbier T.
Weller K.
Kolkhir P.
Author's Affiliation
Københavns Universitet
Charité – Universitätsmedizin Berlin
Université de Montpellier
Erasmus MC
National and Kapodistrian University of Athens
Universität Duisburg-Essen
Sechenov First Moscow State Medical University
Universitat Pompeu Fabra Barcelona
Universitätsmedizin Mainz
Mashhad University of Medical Sciences
Slaski Uniwersytet Medyczny w Katowicach
Guy's Hospital
Universitätsklinikum Carl Gustav Carus Dresden
Centre Hospitalier Universitaire de Grenoble
Siriraj Hospital
Bispebjerg Hospital
Ahvaz Jundishapur University of Medical Sciences
Université Libanaise
Bahçeşehir Üniversitesi
Hospital Italiano de Buenos Aires
Moscow Healthcare Department
Cleveland Clinic Abu Dhabi
State Research Center Institute of Immunology FMBA
University of Nicosia Medical School
Gilbert and Rose-Marie Chagoury School of Medicine
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
Astana Medical University
Center for Human Drug Research
Smolensk State Medical Academy
University of Cape Town Lung Institute
Institut National de Santé Publique, d’Épidémiologie Clinique et de Toxicologie-Liban
Bolnišnica Golnik
Clinica San Carlo
Charité – Universitätsmedizin Berlin
Université de Montpellier
Erasmus MC
National and Kapodistrian University of Athens
Universität Duisburg-Essen
Sechenov First Moscow State Medical University
Universitat Pompeu Fabra Barcelona
Universitätsmedizin Mainz
Mashhad University of Medical Sciences
Slaski Uniwersytet Medyczny w Katowicach
Guy's Hospital
Universitätsklinikum Carl Gustav Carus Dresden
Centre Hospitalier Universitaire de Grenoble
Siriraj Hospital
Bispebjerg Hospital
Ahvaz Jundishapur University of Medical Sciences
Université Libanaise
Bahçeşehir Üniversitesi
Hospital Italiano de Buenos Aires
Moscow Healthcare Department
Cleveland Clinic Abu Dhabi
State Research Center Institute of Immunology FMBA
University of Nicosia Medical School
Gilbert and Rose-Marie Chagoury School of Medicine
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
Astana Medical University
Center for Human Drug Research
Smolensk State Medical Academy
University of Cape Town Lung Institute
Institut National de Santé Publique, d’Épidémiologie Clinique et de Toxicologie-Liban
Bolnišnica Golnik
Clinica San Carlo
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Chronic spontaneous urticaria (CSU), a disease predominantly affecting females, has limited information available on its differences between females and males of varying ages. Objective: To investigate sex differences in age groups regarding disease activity, comorbidities, quality of life (QoL) and treatment patterns in CSU patients. Methods: We analysed Chronic Urticaria Registry (CURE) data, an international real-world registry for patients with chronic urticaria. Patients were recruited via an online platform using a standardized questionnaire. The data were analysed for demographics, age of onset, duration of urticaria, (Urticaria Activity Score [UAS], Urticaria Control Test [UCT], Chronic Urticaria Quality of Life Questionnaire [CU-Q2oL]), family history, systemic symptoms, aggravating factors, comorbidities, smoking and alcohol consumption, laboratory parameters, burden of disease, treatment distribution and response rates, compliance to treatment and adverse events. Comparisons were made among age groups <13, 13–17, 18–30, 31–50, 51–65 and >65 years. Results: Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female. Statistically significant female predominance started at age 31 (<0.001). Compared with males, females showed higher rates of angioedema (59.6 vs. 51.7%; p < 0.001), systemic symptoms (34.6 vs. 25.4%; p < 0.001), sleep disturbance (38.9 vs. 32.5%; p < 0.001), QoL impairment (CU-Q2oL score 32 vs. 27.7; p < 0.001) and lower rates of urticaria control than males in all medication categories (p < 0.05 for all). Females had more concomitant diseases, including asthma, thyroid disease, obesity, autoimmune disease, gastrointestinal disease and depression (p < 0.05 for all). The disease was especially more burdensome and refractory in females aged 51–65 years than males, evidenced by more angioedema and systemic symptoms, worse QoL, lower UCT scores and more emergency visits (p < 0.05 for all). However, these differences were not prominent in the elderly females (>65 years). Conclusion: Compared with males, female CSU patients experience more burdensome disease, which gets worse in midlife. Clinicaltrials.gov (or equivalent) listing (if applicable None).